Page last updated: 2024-10-25

ciglitazone and Diabetic Nephropathies

ciglitazone has been researched along with Diabetic Nephropathies in 3 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.

Research Excerpts

ExcerptRelevanceReference
" CZ ameliorated decrease bioavailability of NO in the diabetic animal."1.35Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. ( Kumar, M; Kundu, S; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2008)
" Long-term administration (12 and 20 weeks) of ciglitazone significantly improved the blood glucose of most of the treated db/db mice."1.27Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice. ( Chang, AY; Diani, AR; Gilchrist, BJ; Hearron, AE; Jodelis, K; Peterson, T; Sawada, G; Wyse, BM, 1986)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sen, U1
Rodriguez, WE1
Tyagi, N1
Kumar, M1
Kundu, S1
Tyagi, SC1
Ohga, S1
Shikata, K1
Yozai, K1
Okada, S1
Ogawa, D1
Usui, H1
Wada, J1
Shikata, Y1
Makino, H1
Diani, AR1
Peterson, T1
Sawada, G1
Jodelis, K1
Wyse, BM1
Gilchrist, BJ1
Hearron, AE1
Chang, AY1

Other Studies

3 other studies available for ciglitazone and Diabetic Nephropathies

ArticleYear
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
    American journal of physiology. Endocrinology and metabolism, 2008, Volume: 295, Issue:5

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epinephrine; Gene E

2008
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
    American journal of physiology. Renal physiology, 2007, Volume: 292, Issue:4

    Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E

2007
Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice.
    Nephron, 1986, Volume: 42, Issue:1

    Topics: Animals; Blood Glucose; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glomerular Mesangium;

1986
chemdatabank.com